Citations

Clear

1526 citation(s) found for "Sun, D".

A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
Escudier, Bernard , Pal, Sumanta K. , Hainsworth, John D. , Choi, YounJeong, Huseni, Mahrukh , Fine, Gregg, Powles, Thomas, McDermott, David F. , Atkins, Michael B. , Motzer, Robert J. , Rini, Brian I. , Fong, Lawrence , Joseph, Richard W. , Stadler, Walter M. , Hutson, Thomas E. , Ravaud, Alain , Bracarda, Sergio , Suárez, Cristina , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 431-431

10.1200/jco.2017.35.6_suppl.431 Get It

431 Background: While targeting VEGF improves outcomes for mRCC pts, resistance invariably develops, often within the first year. Here, we describe the efficacy and safety of atezo (anti-PD-L1) with bev (anti-VEGF) and atezo monotherapy vs sun (TKI) in first-line mRCC. Methods: Treatment-naïve mRCC pts were enrolled in a hypothesis generating Ph II study (IMmotion150; NCT01984242) and randomized to atezo 1200 mg IV q3w + bev 15 mg/kg IV q3w, atezo alone or sun 50 mg PO QD 4 wk on/2 wk off. Crossover to atezo + bev after disease progression was allowed for pts receiving atezo or sun. PD-L1 expression was scored on tumor-infiltrating immune cells (IC, SP142 IHC assay). Coprimary endpoints were PFS (RECIST v1.1 by independent review [IRF]) in ITT pts and pts with PD-L1 expression on ≥ 1% of IC (PD-L1+). Results: Baseline characteristics were comparable across arms and between ITT and PD-L1+ pts. The majority of sun and atezo pts subsequently received atezo + bev. Median survival follow up was 20.7 mo. The PFS HR in ITT pts for atezo + bev vs sun was 1.00 and 1.19 for atezo vs sun. In PD-L1+ pts, the PFS HR for atezo + bev vs sun was 0.64 and 1.03 for atezo vs sun (table). Tx-related Gr 3-4 AEs were seen in 40%, 16% and 57% of pts in the atezo + bev, atezo and sun arms, respectively. AEs leading to death occurred in 3%, 2% and 2% of pts, respectively. Conclusion: Atezo + bev resulted in encouraging antitumor activity in the PD-L1+ subgroup of first-line RCC pts. Atezo + bev safety is consistent with the known profile of atezo and bev individually. The clinical benefit of atezo + bev vs sun will be evaluated in the ongoing Ph III study IMmotion151 (NCT02420821). Clinical trial information: NCT01984242. [Table: see text]
A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma.
Oh, Do‐Youn , Mody, Kabir , Lim, John K. C., Richards, Donald , Borad, Mitesh J. , Hubbard, Joleen M. , Rha, Sun Young

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 294-294

10.1200/jco.2017.35.4_suppl.294 Get It

294 Background: CX-4945 is a first-in-class casein kinase-2 (CK2) threonine kinase small molecule inhibitor. CK2 is pleiotropic and regulates key cellular processes such as proliferation and DNA damage repair, and has been shown to enhance efficacy of gemcitabine (G) and cisplatin (C) in cell line and xenograft CCA model systems. A Phase IB study of G+C with CX-4945 was conducted in advanced cholangiocarcinoma (CCA) patients. Methods: A multi-center “3+3” dose escalation study was conducted in advanced CCA patients. Eligible patients had ECOG PS 0-1 and adequate hematologic, hepatic, and renal function. Primary endpoints were maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Secondary endpoints included pharmacokinetic (PK) analyses, overall toxicity evaluation and preliminary assessment of efficacy. Routine clinical dosing for G (1000 mg/m2) and C (25 mg/m2), both on days 1 and 8 every 21 days, was used. Dose escalation cohort were CX-4945 given twice daily on days 0,1,2 and 7,8,9 at 200 mg (DL1), 400mg (DL2), 600 mg (DL3), 800 mg (DL4) and 1000 (DL5) mg. NCI CTCAE v4.03 was used for toxicity assessment and RECIST v1.1 for efficacy evaluation. Results: Nineteen patients were enrolled (DL1:n = 3; DL2:n = 4 DL3:n = 3; DL4:n = 4; DL5:n = 5). No dose limiting toxicities were encountered. MTD and RP2D were ascertained to be DL5. No grade 3 or 4 toxicities at prevalence > 10% were encountered and the overall toxicity profile of the combination was reflective of standard G+C toxicity profile. At data cut-off, preliminary efficacy evaluation demonstrated disease control rate (CR+PR+SD) of 64% (PR:32%, SD:32% and CR:0%), along with median progression-free survival (PFS) of 5 months (range 0-14 months). PK analyses showed no evidence of drug-drug interactions between G, C and CX-4945. Conclusions: RP2D for G+C with CX-4945 is DL5 (CX-4945 dosed on days 0,1,2 and 7,8,9 at 1000 mg PO bid with standard G and C dosing). Preliminary clinical efficacy and tolerability of the regimen support planned controlled, randomized Phase 2 evaluation. Clinical trial information: NCT02128282.
Cardiovascular safety of phosphodiesterase inhibitors for treating erectile dysfunction in elderly men
Xu, Rende , He, Ben , Pu, Jun , Peterson, Karen M.

Mayo Clinic

Cochrane Database of Systematic Reviews | March 6, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd011178.pub2 Get It

Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases
Haycock, Philip , Burgess, Stephen , Nounu, Aayah , Zheng, Jie , Okoli, George N. , Wade, Kaitlin H. , Timpson, Nicholas J. , Evans, David M. , Willeit, Peter , Aviv, Abraham , Gaunt, Tom R. , Hemani, Gibran , Mangino, Massimo , Ellis, Hayley, Kurian, Kathreena M. , Pooley, Karen A. , Eeles, Rosalind A. , Lee, Jeffrey E. , Fang, Shenying , Chen, Wei V., Law, Matthew H. , Bowdler, Lisa, Iles, Mark M. , Worrall, Bradford B. , Markus, Hugh S. , Hung, Rayjean J., Amos, Chris, Thompson, Deborah J. , O’Mara, Tracy A. , Wolpin, Brian M. , Ámundadóttir, Laufey T. , Trichopoulou, Antonia , Onland‐Moret, N. Charlotte , Lund, Eiliv , Canzian, Federico , Severi, Gianluca , Overvad, Kim , Gunter, Marc J. , ­Tumino, ­Rosario , Svenson, Ulrika, Rij, André van, Baas, Annette F., Bown, Matthew J. , Samani, Nilesh J. , t’Hof, Femke N.G. van, Tromp, Gerard , Jones, Gregory T. , Kuivaniemi, Helena , Elmore, James R. , Johansson, Mattias , McKay, James , Scélo, Ghislaine , Carreras‐Torres, Robert , Gaborieau, Valérie , Brennan, Paul , Bracci, Paige M. , Olson, Sara H. , Gallinger, Steven , Li, Donghui , Petersen, Gloria M. , Han, Jiali , Abnet, Christian C. , Freedman, Neal D. , Aben, Katja K.H. , Kiemeney, Lambertus A. , Vermeulen, Sita H. , Walsh, Kyle M. , Wrensch, Margaret , Rice, Terri, Turnbull, Clare , Litchfield, Kevin , Paternoster, Lavinia , Standl, Marie , Mijatovic, Vladan, Sapkota, Yadav , Zondervan, Krina T. , Nyholt, Dale R. , Heel, David A. van , Arking, Dan E. , Ashar, Foram N., Sotoodehnia, Nona, Woo, Daniel , Comeau, Mary E. , Brown, W. Mark , Silverman, Edwin K. , Hokanson, John E. , Hui, Jennie , Thompson, Philip J. , Morrison, Alanna C. , Smith, Nicholas L. , Christiano, Angela M. , Petukhova, Lynn , Betz, Regina C. , Zhang, Xuejun, Zhu, Caihong, Langefeld, Carl D. , Thompson, Susan D. , Wang, Feijie , Fingerlin, Tasha E. , Rotter, Jerome I. , Cotch, Mary Frances , Jensen, Richard A., Munz, Matthias , Dommisch, Henrik , Schäefer, Arne S. , Ollila, Hanna M. , Hillary, Ryan P. , Zeng, Chenjie , Zheng, Wei , Shu, Xiao-Ou , Reis, André , Uebe, Steffen , Hüffmeier, Ulrike , Kawamura, Yoshiya, Otowa, Takeshi , Sasaki, Tsukasa, Dávila, Sonia , Siminovitch, Katherine A. , Bei, Jin‐Xin , Zeng, Yi‐Xin , Chen, Bowang , Franke, Andre, Fischer, Annegret, Ellinghaus, David , Flores, Carlos , Noth, Imre , Ma, Shwu‐Fan , Foo, Jia Nee , Liu, Jianjun , Cox, David G. , Delattre, Olivier , Mirabeau, Olivier , Skibola, Christine F., Tang, Clara Sze-Man , Garcia-Barceló, Mercè, Su, Wen-Hui , Chang, Yu‐Sun , Wade, Tracey , Lee, Chaeyoung , Kubo, Michiaki , Cha, Pei-Chieng , Nakamura, Yusuke, Levy, Daniel , Hunt, S. E., Spector, Tim D. , Soranzo, Nicole , Barr, R. Graham, Kahali, Bratati , Speliotes, Elizabeth K. , Yerges-Armstrong, Laura M. , Cheng, Ching‐Yu , Wong, Tien Yin , Fogh, Isabella , Powell, John , Rice, Kenneth , Relton, Caroline L. , Martin, Richard M. , Smith, George Davey , Hung, Rayjean J. , Bowden, Jack , Yang, Qiong , Spurdle, Amanda B. , Stolzenberg‐Solomon, Rachael Z. , Duell, Eric J. , Neale, Rachel Ε. , Risch, Harvey A. , Klein, Alison P. , Taylor, Philip R. , Maris, John M. , Wiencke, John K. , Abecasis, Gonçalo R. , SanGiovanni, John Paul , Li, Yong , Low, Siew‐Kee , Montgomery, Grant W. , Hunt, Karen A. , Rosand, Jonathan M. , Cho, Michael H. , Ferreira, Manuel A. R. , Felix, Janine F. , Fan, Xing Hua , Xu, Lin , Schwartz, David A. , Han, Fang , Albagha, Omar , Ralston, Stuart H. , Sasaki, Tsukasa, Hibberd, Martin Lloyd , Xie, Gang , Försti, Asta , Landi, Stefano , Ellinghaus, David , Kim, Jong‐Won , Chang, Kai‐Ping , Martin, Nicholas G. , Gordon, Scott D. , Kimura, Masayuki , Hwang, Shih‐Jen , Manichaikul, Ani , Barr, R. Graham, Jonas, Jost B , Lin, Kuang , Amundadottir, Laufey , Kiemeney, Lambertus A , Eeles, Rosalind A , van Heel, David A , Gunter, Marc J , Canzian, Federico , Hung, Rayjean J , O'Mara, Tracy A , Abnet, Christian C , Haycock, Philip , Tumino, Rosario , Han, Jiali , Martin, Richard M , Severi, Gianluca , Reis, André , Zheng, Wei , Rotter, Jerome I , Carreras-Torres, Robert , Law, Matthew H , Davey Smith, George , Johansson, Mattias , Iles, Mark M , Morrison, Alanna C , Rice, Ken , Freedman, Neal D , Foo, Jia Nee , Levy, Daniel , Rice, Kenneth , Sapkota, Yadav , Wong, Tien Y , Liu, Jing

Mayo Clinic

JAMA Oncology | February 27, 2017 | Volume: 3 | Issue: 5 | Pages: 636

10.1001/jamaoncol.2016.5945 | PMID 28241208 Get It

Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report.
Sun, Maxine , Gandaglia, Giorgio , Karakiewicz, Pierre I. , Kim, Simon P. , Trinh, Quoc‐Dien , Hu, Jim C. , Nguyen, Paul L. , Choueiri, Toni K. , Abdollah, Firas , Trinh, Quoc‐Dien

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 32 | Issue: 4_suppl | Pages: 334-334

10.1200/jco.2014.32.4_suppl.334 Get It

334 Background: Radical cystectomy (RC) represents the standard of care for patients with muscle-invasive urothelial carcinoma of the urinary bladder (UCUB). Alternative organ-conserving treatments such as chemotherapy and/or radiotherapy have gained interest. We sought to compare survival outcomes of patients according to treatment modalities, in a stage-for-stage analysis. Methods: We relied on the Surveillance, Epidemiology, and End Results Medicare-linked database to identify 12,950 patients diagnosed with T2–T4a N0/x M0 UCUB between years 1992 and 2009. Treatment types include RC (n=5207), chemotherapy/radiation (n=2,669), and surveillance (n=5,074). Following instrumental variable analysis, Cox- and competing-risks regression analyses were performed for prediction of overall survival (OS) and cancer-specific mortality (CSM), respectively. All analyses were stratified according to disease stage (T2, T3, T4a). Results: After adjusting for potential confounders, OS was more favorable for RC relative to chemotherapy/radiation (hazard ratio [HR]: 1.57, 95% confidence interval [CI]: 1.02–2.40) or surveillance (HR: 1.82, 95% CI: 1.20–2.78) in patients with T2 UCUB. For the same stage, CSM rates were lower in the surgery group compared to chemotherapy/radiation (HR: 2.05, 95% CI: 1.14–3.67) or surveillance (HR: 1.95, 95% CI: 1.09–3.48). When analyses focused on individuals with more advanced disease (T3–T4a), no statistically significant difference was observed between chemotherapy/radiation relative to RC for both OS and CSM. Conclusions: In the current retrospective population-based cohort, RC was associated with improved survival outcomes relative to its alternative treatment counterparts. However, this effect was only observable in patients with T2 disease. Conversely, no difference between chemotherapy/radiation vs. surgery was noted in patients with more advanced disease stage.
Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC).
Yuan, Tiezheng , Costello, Brian A. , Tan, Winston , Nandy, Debashis, Longenbach, Sherri, Kohli, Manish , Huang, Xiaoyi , Sun, Zhifu , Quevedo, Fernando , Wang, Liang

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 32 | Issue: 4_suppl | Pages: 260-260

10.1200/jco.2014.32.4_suppl.260 Get It

260 Background: The purpose of this study was to evaluate cell free nucleic acid based biomarkers for prognosis in mCRPC stage. Methods: Uniformly collected blood from mCRPC patients was processed for plasma which was used for exosomal RNA extraction. RNA sequencing was applied to examine microRNA (miRNA) profiles initially in a discovery cohort of 23 mCRPC patients. The sequences from fastq files were mapped to human miRBase (release 19) for known miRNA read counts. A software package (miRDeep2) was used for novel miRNA prediction. Cox regression was used for association of candidate miRNAs with overall survival (OS), defined as time from development of mCRPC to death or last follow up after adjusting for Gleason Score (GS) and time on androgen deprivation (AD) for hormone sensitive disease. miRNAs significantly associated with OS (FDR<0.05) were then validated in an independent cohort of 100 mCRPC subjects using univariate Cox regression. Results: RNA sequencing generated >10 million mappable reads per specimen in the discovery cohort. Among these reads ~50% were known miRNAs which included 1237 unique RNA sequences. Due to low abundance of most RNA transcripts, only miRNAs (n=250) with >/= 32 reads (on average) were analyzed. Four mRNAs (miR-1290, -1246, -375 and a predicted miRNA on chr. 12) were associated with OS(FDR<0.05). These were evaluated as prognotic markers in the independent cohort (N=100) using real time RT-PCR. Median time on AD for this cohort prior to progression to mCRPC was 35.7 (range: 3.5-136) months; median GS was 7; median follow up after mCRPC development was 12.5 (1-41) months at which time 28 patients had died. Elevated expression for miR-1290 and -375 were associated with shorter OS after adjusting for GS and AD time with a Hazard Ratio (HR) for miR-375 of 1.19 (CI: 1.006-1.18); (p=0.04) and a HR for miR1290 of 1.58 (CI:1.01-2.4); (p=0.04). A stronger association with shorter OS was observed for elevated expression of both miRs-HR of 2.02 (CI: 1.1-3.6) (p=0.01). Conclusions: Blood-based nucleic acid assays are easily accessible for biomarker development in mCRPC. Results from this study suggest specific exosomal miRs are of prognostic value in mCRPC and should be validated in larger cohorts.
Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis.
Kiechle, Jonathan, Wang, Elyn, Gross, Cary P. , Abouassaly, Robert , Cherullo, Edward E., Smaldone, Marc C. , Shah, Nilay D., Sun, Maxine , Kim, Simon P. , Yu, James B. , Trinh, Quoc‐Dien

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 7_suppl | Pages: 89-89

10.1200/jco.2015.33.7_suppl.89 Get It

89 Background: Lymph node counts have been proposed as a quality metric for patients undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND). It is unclear whether surgical approach and hospital characteristics independently determine the number of lymph nodes removed at PLND. Therefore, we assessed the variation in lymph node counts from a population-based cohort of patients undergoing surgery for intermediate and high-risk prostate cancer. Methods: Using the National Cancer Database, we identified all surgically treated patients diagnosed with pre-treatment intermediate or high-risk prostate cancer from 2010 to 2011. The primary outcome was the number of lymph nodes retrieved at the time of RP. Generalized estimating equations were used to assess for differences in the adjusted number of lymph nodes retrieved after accounting for patient and hospital characteristics and surgical approach. Results: Overall, 35,876 patients were diagnosed with intermediate (61.2%) and high-risk (38.8%) prostate cancer and underwent RP and PLND. On multivariable analysis, open radical prostatectomy (ORP) and high volume and academic hospitals were independently associated with greater lymph node counts compared to robotic-assisted radical prostatectomy (RARP) and medium/low and community hospitals, respectively (all p<0.001). After adjusting for patient and hospital variables, higher adjusted lymph nodes counts were observed for ORP compared to RARP (7.1 vs. 6.1; p<0.001). Adjusted counts were also higher for high volume compared to medium/low volume hospitals (7.8 vs. 5.9; p<0.001), and academic compared to community hospitals (7.3 vs. 5.6; p<0.001). Conclusions: Among patients with aggressive prostate cancer treated with RP and PLND, lymph node counts varied by surgical approach and hospital characteristics.
Baseline subject characteristics to predict compliance with study-mandated prostate biopsy in men at risk of prostate cancer: Results from REDUCE.
Fischer, Sean, Sun, Xizi, Castro, Ramiro, Andriole, Gerald L. , Vidal, Adriana C. , Freedland, Stephen J. , Fischer, Sean, Howard, Lauren E. , Moreira, Daniel M. , Vidal, Adriana C.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 2_suppl | Pages: 6-6

10.1200/jco.2016.34.2_suppl.6 Get It

6 Background: Study compliance is crucial when the study outcome is determined by an invasive procedure, such as prostate biopsy. To investigate predictors of compliance in study-mandated prostate biopsies, we analyzed demographic, clinical and reported lifestyle data from the REDUCE trial. Methods: We retrospectively identified 8,062 men from REDUCE with at least 2-years of follow-up, and used multivariable logistic regression to test the association between baseline demographic and clinical characteristics and undergoing the study-mandated prostate biopsy at 2 years. We then examined whether missing any of these data was associated with undergoing a biopsy. Results: In REDUCE, 20% of men did not undergo a 2-year biopsy.On multivariable analysis, non-North American region was predictive of 35-55% increased likelihood of undergoing a 2-year biopsy (p ≤ 0.001). Being enrolled at a center that enrolled >10 subjects (2nd and 3rd tertile) was associated with a 40-49% increased likelihood of undergoing a 2-year biopsy (p < 0.001). Missing one or more baseline variables was associated with a 25% decreased likelihood of undergoing a 2-year biopsy (OR = 0.75; p = 0.002). Conclusions: In REDUCE, men outside North America, those at higher volume centers, and those with complete baseline data were more likely to undergo study mandated 2-year biopsies. Given prostate biopsy is becoming increasingly utilized as an endpoint in trials that are often multi-national, regional differences in compliance should be considered when designing future trials. Likewise, efforts are needed to ensure compliance in low-volume centers or among subjects missing baseline data.
Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.
Chanan‐Khan, Asher , Fraser, Graeme , Silva, Rodrigo Santucci, Pylypenko, Halyna, Janssens, Ann , Pristupa, Alexander , Mayer, Jiřı́ , Dilhuydy, Marie‐Sarah, Loscertales, Javier, Avigdor, Abraham , Rule, Simon , Sun, Steven , Mahler, Michelle, Salman, Mariya, Howes, Angela, Hallek, Michael , Cramer, Paula , Demırkan, Fatih , Grosicki, Sebastian , Bartlett, Nancy L.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 18_suppl | Pages: LBA7005-LBA7005

10.1200/jco.2015.33.18_suppl.lba7005 Get It

LBA7005 Background: The phase III HELIOS study evaluated the first-in-class, oral covalent BTK inhibitor ibrutinib in combination with BR (BR+ibr) vs BR plus placebo (BR+plb) in patients (pts) with previously treated CLL/SLL. The preplanned interim analysis reported here showed that the primary end point was met, upon which the IDMC recommended unblinding the study. Methods: Pts received BR ( ≤ 6 cycles) and were randomized 1:1 to ibr (420 mg daily) or plb. Purine analog refractoriness was a stratification factor. Pts with del17p ( > 20% of cells) were excluded. Primary end point was independent review committee (IRC)-assessed progression-free survival (PFS). Secondary end points included overall survival (OS) and overall response rate (ORR) per IRC. Results: 578 pts were randomized (289 per arm); median age 64 yrs; 38% Rai Stage III/IV; median 2 prior therapies. 6 cycles of BR were completed in 83% and 78% of pts in the ibr and plb arms, respectively. At a median follow-up of 17.2 months, IRC-assessed PFS was significantly longer with BR+ibr vs BR+plb (median not reached vs 13.3 months; HR: 0.203, 95% CI: 0.150-0.276, P< 0.0001); PFS results were consistent across high-risk subgroups. ORR and CR/CRi rates were 82.7% vs 67.8% (P< 0.0001) and 10.4% vs 2.8%. Median OS was not reached. 90 pts (31%) in the BR+plb arm with confirmed PD crossed over to receive ibr, as permitted per the protocol. Incidence of most AEs was similar between arms. The most common all-grade AEs with BR+ibr and BR+plb were neutropenia (58.2% vs 54.7%) and nausea (36.9% vs 35.2%); most common grade 3/4 AEs were neutropenia (53.7% vs 50.5%) and thrombocytopenia (15.0% each arm). Rates of grade 3/4 atrial fibrillation were 2.8% and 0.7%, and major hemorrhage were 2.1% and 1.7%. Fatigue (FACIT-Fatigue) was improved with BR+ibr vs BR+plb. Conclusions: The addition of ibr to BR reduced the risk of progression or death by 80% compared with BR+plb. ORR was also significantly improved. Safety of BR+ibr was consistent with the known profiles for BR and ibr. The data further support ibr as an important treatment option for pts with previously treated CLL/SLL. Clinical trial information: EudraCT No. 2012-000600-15; UTN No. U1111-1135-3745.
Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis.
Sun, Weijing , Nelson, David , Poordad, F., Leong, Stephen , Teitelbaum, Ursina , Fox, N. L., O’Neil, Bert H. , Alberts, Steven R. , Woods, Laura M.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 29 | Issue: 4_suppl | Pages: 261-261

10.1200/jco.2011.29.4_suppl.261 Get It

261 Background: Mapatumumab is a fully human agonist monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Sorafenib targets Mcl-1, a key TRAIL resistance protein, and accordingly could enhance mapatumumab's pro-apoptotic activity. Based on this and on preclinical data on mapatumumab in HCC cell lines, the current dose-escalation study is evaluating mapatumumab in combination with sorafenib in patients with advanced HCC. Methods: Eligible patients had advanced HCC, Child-Pugh A or Model for End-Stage Liver Disease score < 15, and were positive for hepatitis B surface antigen or hepatitis C antibody. Intravenous mapatumumab was administered at 3, 10 or 30 mg/kg every 21 days with sorafenib (400 mg twice daily) until disease progression or unacceptable toxicity. Dose-limiting toxicities (DLTs) included events considered at least possibly related to mapatumumab and/or its interaction with sorafenib. Tumor measurements were performed every 2 cycles. Dose escalation required at least 3 patients in a cohort to receive >= 50% of full-dose sorafenib in the first 2 cycles. Results: To date, 19 patients have been enrolled in the 3 mg/kg (n=6), 10 mg/kg (n=9) and 30 mg/kg (n=4) cohorts and have received a median of 4 cycles (range 1 to 24 cycles); 4 patients have received >= 11 cycles. The maximum tolerated dose has not been reached. DLTs that prompted expansion of the 3 mg/kg and 10 mg/kg cohorts were elevations of amylase and/or lipase (1 at 3 mg/kg, 1 at 10 mg/kg). Other Grade 3-4 events considered at least possibly related to mapatumumab and/or its interaction with sorafenib included hepatic pain (1/17), thrombocytopenia (1/17), increased aspartate aminotransferase (1/17), increased lipase (1/17), and increased gamma-glutamyltransferase (1/17). Two patients have had a partial response and 4 patients have had stable disease lasting > 12 weeks, based on investigator assessment. Conclusions: Mapatumumab was well-tolerated at doses up to 30 mg/kg in combination with sorafenib in patients with HCC and viral hepatitis. A randomized phase II study of this combination in patients with advanced HCC is planned. [Table: see text]